Tags

Type your tag names separated by a space and hit enter

Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study.
Urol Int. 2010; 84(4):400-6.UI

Abstract

OBJECTIVES

To evaluate the efficacy and safety of Serenoa repens + selenium and lycopene (Profluss) versus S. repens alone for the treatment of category IIIa chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

PATIENTS AND METHODS

102 patients with IIIa CP/CPPS were enrolled and randomized into two groups each to receive Profluss or S. repens alone for 8 weeks. Evaluation was based on results of the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), IPSS, maximum peak flow rate (MPFR), and PSA measurements at baseline and at weeks 4, 8 and 8 after the end of treatment. The primary endpoint was a >50% reduction in NIH-CPSI score. Secondary endpoints evaluated were MPFR, IPSS, PSA and white blood cell count.

RESULTS

No patients withdrew from the study. The mean NIH-CPSI score decreased significantly (p < 0.001) in both groups; we observed a decrease in the total score from 27.45 to 13.27 in group 1 (-51.64%) and from 27.76 to 20.62 in group 2 (-26.06%). IPSS improved significantly (p < 0.001) in both arms, but more in group 1. PSA and white blood cell count decreased significantly (p < 0.007) only in group 1. The MPFR improved more in group 1 (p < 0.005).

CONCLUSION

Profluss is a triple therapy that is safe and well tolerated. It ameliorates symptoms associated with IIIa CP/CPPS.

Authors+Show Affiliations

Departments of Urology, University of Messina, Messina, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

20332612

Citation

Morgia, G, et al. "Treatment of Chronic Prostatitis/chronic Pelvic Pain Syndrome Category IIIA With Serenoa Repens Plus Selenium and Lycopene (Profluss) Versus S. Repens Alone: an Italian Randomized Multicenter-controlled Study." Urologia Internationalis, vol. 84, no. 4, 2010, pp. 400-6.
Morgia G, Mucciardi G, Galì A, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int. 2010;84(4):400-6.
Morgia, G., Mucciardi, G., Galì, A., Madonia, M., Marchese, F., Di Benedetto, A., Romano, G., Bonvissuto, G., Castelli, T., Macchione, L., & Magno, C. (2010). Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urologia Internationalis, 84(4), 400-6. https://doi.org/10.1159/000302716
Morgia G, et al. Treatment of Chronic Prostatitis/chronic Pelvic Pain Syndrome Category IIIA With Serenoa Repens Plus Selenium and Lycopene (Profluss) Versus S. Repens Alone: an Italian Randomized Multicenter-controlled Study. Urol Int. 2010;84(4):400-6. PubMed PMID: 20332612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. AU - Morgia,G, AU - Mucciardi,G, AU - Galì,A, AU - Madonia,M, AU - Marchese,F, AU - Di Benedetto,A, AU - Romano,G, AU - Bonvissuto,G, AU - Castelli,T, AU - Macchione,L, AU - Magno,C, Y1 - 2010/03/24/ PY - 2009/07/22/received PY - 2009/10/12/accepted PY - 2010/3/25/entrez PY - 2010/3/25/pubmed PY - 2010/9/21/medline SP - 400 EP - 6 JF - Urologia internationalis JO - Urol. Int. VL - 84 IS - 4 N2 - OBJECTIVES: To evaluate the efficacy and safety of Serenoa repens + selenium and lycopene (Profluss) versus S. repens alone for the treatment of category IIIa chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). PATIENTS AND METHODS: 102 patients with IIIa CP/CPPS were enrolled and randomized into two groups each to receive Profluss or S. repens alone for 8 weeks. Evaluation was based on results of the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), IPSS, maximum peak flow rate (MPFR), and PSA measurements at baseline and at weeks 4, 8 and 8 after the end of treatment. The primary endpoint was a >50% reduction in NIH-CPSI score. Secondary endpoints evaluated were MPFR, IPSS, PSA and white blood cell count. RESULTS: No patients withdrew from the study. The mean NIH-CPSI score decreased significantly (p < 0.001) in both groups; we observed a decrease in the total score from 27.45 to 13.27 in group 1 (-51.64%) and from 27.76 to 20.62 in group 2 (-26.06%). IPSS improved significantly (p < 0.001) in both arms, but more in group 1. PSA and white blood cell count decreased significantly (p < 0.007) only in group 1. The MPFR improved more in group 1 (p < 0.005). CONCLUSION: Profluss is a triple therapy that is safe and well tolerated. It ameliorates symptoms associated with IIIa CP/CPPS. SN - 1423-0399 UR - https://www.unboundmedicine.com/medline/citation/20332612/Treatment_of_chronic_prostatitis/chronic_pelvic_pain_syndrome_category_IIIA_with_Serenoa_repens_plus_selenium_and_lycopene__Profluss__versus_S__repens_alone:_an_Italian_randomized_multicenter_controlled_study_ L2 - https://www.karger.com?DOI=10.1159/000302716 DB - PRIME DP - Unbound Medicine ER -